Synthetic gastric pentadecapeptide

BPC-157

CAS: 137525-51-0 MW: 1419.5 g/mol Formula: C₆₂H₉₈N₁₆O₂₂

1. Identity

FieldValue
Proposed INNNone — no INN assigned. Investigational. [Academic secondary source — WHO INN database]
Common namesBPC-157, BPC 157, Body Protection Compound-157, pentadecapeptide BPC-157, Bepecin
Development codesPL-10, PLD-116, PL 14736 (Pliva / Diagen IBD program), PCO-02 (oral tablet form, Diagen)
CAS Registry No.137525-51-0 [Academic secondary source — ChemicalBook; CAS]
PubChem CID9941957 (free base); 155977614 (acetate salt) [Academic secondary source — PubChem]
UNII (FDA)8ED8NXK95P (free base); PAR2FC72XP (acetate) [Regulatory document — FDA UNII / NCATS Inxight]
Molecular formulaC₆₂H₉₈N₁₆O₂₂ (free base)
Average MW1419.5 g/mol
SequenceH-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
ClassSynthetic gastric pentadecapeptide; partial sequence of a putative 62-residue gastric juice “body protection compound”
DrugBank / BNF / USPNo monograph. Not in USP/NF; not in BNF; not in DrugBank as an approved drug

The 15-amino-acid sequence is described by its discoverers as a fragment of a larger ~62-residue protein isolated from human gastric juice. The 62-residue parent has never been independently confirmed in proteomic databases as a discrete annotated protein, and BPC-157 itself does not appear in UniProt as a naturally circulating peptide. [Academic secondary source — UniProt search, May 2026]

2. History and Development

  • Early 1990s — Discovery. P. Sikiric, S. Seiwerth, and colleagues at the University of Zagreb School of Medicine (Croatia) reported a “gastric juice protein with cytoprotective activity” and named the 15-amino-acid synthetic fragment “BPC-157.” First descriptions in J Physiol (Paris) and Croatian/regional pharmacology journals from 1993 onward. [Peer-reviewed preclinical study — Sikiric et al. 1993 J Physiol Paris] 🔴
  • Late 1990s–early 2000s — Pliva development. Pliva (Zagreb), through its research subsidiary later spun out as Diagen, developed the peptide under codes PL-10, PLD-116, and finally PL 14736 for inflammatory bowel disease. ⚠️
  • 2002–2005 — Human program. Veljaca et al. presented Phase 1 healthy-volunteer pharmacokinetic and tolerability data in 2002–2003 (rectal/oral); Ruenzi et al. presented a multicentre randomised double-blind placebo-controlled Phase 2 trial of PL 14736 enema in mild-to-moderate ulcerative colitis at Digestive Disease Week 2005. Both appeared only as conference abstracts (Gut 2003;51:A309; Gastroenterology 2005;128:A584). Neither reached full peer-reviewed publication. [Conference abstracts — Veljaca 2003; Ruenzi 2005] ⚠️
  • Post-2005 — Investigational pause. Pliva was acquired by Barr (2006), then by Teva (2008). Active human development of PL 14736 appears to have ceased; no Phase 3 program was initiated.
  • 2010s — Grey-market emergence. BPC-157 entered the “research peptide” supply chain and was rapidly adopted in bodybuilding, biohacking, and sports-recovery communities. No regulator approved any indication.
  • 2015 — Diagen PCO-02 tablet trial. Phase 1 PK/safety of oral PCO-02 tablets in healthy volunteers registered (NCT02637284); listed as completed/withdrawn with results withheld. [Clinical trial registry]
  • 2022 — WADA prohibition. Added to the WADA Prohibited List under S0 effective 1 January 2022. [Anti-doping document — WADA 2022 Prohibited List]
  • 2023 — FDA Category 2. Placed on the FDA’s 503A interim Category 2 (“significant safety risks”) list 29 September 2023. [Regulatory document]
  • 2024 — TGA scheduling. Australia scheduled BPC-157 as Schedule 4 + Appendix D clause 5 (possession without authority illegal), effective 1 June 2024. [Regulatory document — TGA Final Decision]
  • 2025 — Józwiak critical review and Sikiric-group rebuttal. Pharmaceuticals (MDPI) published the first major adversarial methodological critique of the BPC-157 literature, followed by a formal comment-and-reply exchange (see Section 7.5). 🔴
  • February 2026 — FDA nomination withdrawn. Per the FDA’s currently published 503A status document, the original BPC-157 nominations were withdrawn by the nominators; BPC-157 was removed from Category 2. FDA simultaneously announced PCAC consultation scheduled for 23 July 2026 on whether to add BPC-157 free base / BPC-157 acetate to the 503A bulks list. [Regulatory document]

The Sikiric / Seiwerth group at Zagreb has remained the dominant producer of preclinical data across the entire 30-year history. 🔴

3. Mechanism of Action

Demonstrated in humans (very limited)

  • Tolerability and PK after rectal / oral administration (PL 14736 enema; PCO-02 oral tablet): the only directly characterised human pharmacology. Plasma exposure was reported as low and short-lived consistent with rapid peptidase degradation; no defined PD biomarker was established. [Conference abstract — Veljaca 2003 Gut] ⚠️
  • No human study has confirmed any specific molecular target engagement. No validated PD assay in humans.

Proposed / preclinical (extensive — animal and cell models)

All of the following are derived from preclinical models, predominantly rodent, and the majority originate from the Sikiric / Seiwerth group at Zagreb.

  • Nitric oxide (NO) system modulation. Counter-regulation of L-NAME–induced lesions and rescue by L-arginine; proposed central role of eNOS and Src-Caveolin-1 signalling. [Peer-reviewed preclinical — Sikiric et al., multiple 1997–2024] 🔴 (Independent partial replication: Chang Gung group, Nat Sci Rep 2020.)
  • VEGFR2 activation and upregulation; pro-angiogenic effect. CAM assay, endothelial tube formation, rat hindlimb ischaemia — increased VEGFR2 expression, internalisation, Akt-eNOS phosphorylation. [Peer-reviewed preclinical — Hsieh et al. 2017 J Mol Med PMID 27847966] — independent partial replication (Chang Gung, Taiwan).
  • Growth hormone receptor upregulation in tendon fibroblasts. [Peer-reviewed preclinical — Chang et al. 2014 Molecules PMID 25415479] — Chang Gung group, independent of Zagreb.
  • FAK / paxillin pathway in tendon outgrowth and cell migration. [Peer-reviewed preclinical — Chang et al. 2011 J Appl Physiol]
  • Dopaminergic and serotonergic modulation; gut-brain axis claims. Rodent models of haloperidol catalepsy, ethanol withdrawal, MPTP neurotoxicity. [Peer-reviewed preclinical — Sikiric group, multiple] 🔴
  • Anti-ulcer / cytoprotective effects in alcohol-, NSAID-, cysteamine-, and stress-induced gastric injury. [Peer-reviewed preclinical — Sikiric group, 1990s–2024] 🔴
  • Tendon, ligament, muscle and bone healing acceleration in transected-Achilles, transected-quadriceps, and segmental defect rat models. [Peer-reviewed preclinical — Staresinic, Krivic, Mihaljevic, Pevec, Sikiric et al. 2003–2010] 🔴
  • Reported pharmacokinetics in non-human species: rapid plasma clearance, plasma t½ in minutes, hepatic metabolism, renal excretion. [Peer-reviewed preclinical — He et al. 2022]

Single-group dependency flag 🔴: The Vasireddi 2025 systematic review identified 36 indexed musculoskeletal-relevant studies between 1993 and 2024; the large majority of positive efficacy reports carry the Sikiric / Seiwerth lab as author block. [Peer-reviewed systematic review — Vasireddi 2025 HSS J PMID 40756949]

4. Regulatory Status

4.1 Drug-regulatory status

  • FDA (USA). Never approved for any indication. No NDA, BLA, or IND publicly disclosed beyond the historical PL 14736 / PCO-02 work.
    • 503A bulks list history: Originally nominated; placed in Category 2 (“nominated bulk drug substances that raise significant safety risks”) on 29 September 2023.
    • Current status (May 2026): The FDA’s currently published nomination tracking document records that BPC-157 has been removed from Category 2 because the nominations were withdrawn by the nominators. The FDA has announced PCAC consultation on 23 July 2026 regarding potential inclusion of BPC-157 (free base) and BPC-157 acetate as related bulk drug substances on the 503A list. As of this review date the substance has neither Category 1 (allowed) nor Category 2 (significant-risk) status pending the PCAC outcome. Public statements by HHS Secretary R.F. Kennedy Jr. on 27 February 2026 anticipated reclassification toward Category 1, but the FDA’s formal action so far is nomination withdrawal plus advisory-committee referral, not Category 1 listing. [Regulatory document — FDA Bulk Drug Substances Nominated for Compounding; FDA Advisory Committee Calendar 23–24 July 2026] [News — BioPharma Dive May 2026]
    • 503B outsourcing: Not on the 503B bulks list; no outsourcing facility may legally compound it.
    • GDUFA / orphan / breakthrough: None.
  • EMA. No marketing authorisation, no orphan designation, no scientific advice on file as of May 2026.
  • MHRA (UK). Not approved. Not a controlled drug. No POM listing for the active substance specifically; falls under general unapproved-medicine controls.
  • TGA (Australia). Schedule 4 (Prescription Only Medicine) plus Appendix D clause 5 (“Poisons for which possession without authority is illegal”). Interim decision ACMS-43 / ACCS-37 / Joint ACMS-ACCS-35 November 2023; final decision early 2024; implementation 1 June 2024. This is one of the strictest national positions globally; the mechanism is Schedule 4 + Appendix D, not Schedule 10. [Regulatory document — TGA Notice of Final Decision March 2024]
  • Health Canada. Not approved. No DIN; not in the Drug Product Database; not a listed Natural Health Product. Public advisories issued against unauthorised online vendors (e.g. Prime Research, Sherbrooke QC seizure).
  • PMDA (Japan). Not approved.
  • NMPA (China). Not approved.
  • MFDS (South Korea). Not approved.
  • GRLS (Russia). No registration identified as of May 2026. (Russia’s domestic peptide ecosystem is dominated by Khavinson-school cytogens; BPC-157 is Croatian-developed and has not entered the state register.)
  • WHO Essential Medicines List. Not listed.

4.2 Anti-doping status — MANDATORY

  • WADA Prohibited List 2026. BPC-157 is prohibited at all times (in-competition and out-of-competition) under Section S0 — Non-Approved Substances. Added effective 1 January 2022; status unchanged in 2023, 2024, 2025, 2026 lists. WADA, USADA, and Sport Integrity Australia/Canada all classify it under S0. Some secondary commentary describes overlap with S2.5 (growth factors) given the proposed VEGFR2/GH-receptor mechanism, but the operative listing remains S0 specifically. [Anti-doping document — WADA 2026 Prohibited List]
  • In-competition vs out-of-competition. Prohibited at all times.
  • TUE eligibility. Not available — TUEs require an approved medical use, which BPC-157 does not have in any jurisdiction.
  • NCAA banned-drug-class status. Not individually named, but captured under “peptide hormones, growth factors, related substances and mimetics” and the catch-all “any other substance with a similar chemical structure or biological effect” residual clause.
  • DoD / OPSS status. BPC-157 is on the U.S. Department of Defense Prohibited Dietary Supplement Ingredients List under DoDI 6130.06. OPSS publishes a dedicated substance profile labelling it an unapproved drug and prohibited for service-member use. [Regulatory document — OPSS DoD list, updated 20 March 2026]
  • Global DRO cross-check date. Cross-checked against globaldro.com on 14 May 2026: BPC-157 returns “Prohibited” across US/UK/Canada/Japan athlete queries (all sports, all times).
  • Detection window. Cox, Miller & Eichner (Drug Test Anal 2017, PMID 28371416) characterised in-vitro metabolism and developed a weak-cation-exchange SPE LC-MS/MS method; intact BPC-157 and metabolites detectable in urine for ≥72 h post-administration; some commercial labs report stability up to ~4 days. No WADA-harmonised Technical Document published specifically for BPC-157.
  • Notable sanctions and precedents (selected):
    • Emma Brooks — U SPORTS volleyball (MacEwan). 4-year sanction, announced 7 April 2025 by CCES, for non-analytical admission of BPC-157 and TB-500 use between August–September 2024.
    • Mikal Thrones — powerlifter. 5-year sanction announced 24 February 2025 by CCES; analytical findings of metandienone, drostanolone, RAD140, LGD-4033, GW501516 plus admitted BPC-157 use; aggravating-circumstances uplift applied.
    • Kamryn Lute — U.S. speed skater, age 19 at time of sanction. 1-year ban (2024) following use of a product containing BPC-157 reportedly recommended by a medical provider. ⚠️ (Reported via secondary sources; original USADA decision document not directly retrievable.)
    • Sport Integrity Canada (formerly CCES) issued a formal reminder on 27 April 2026 that BPC-157 and other non-approved peptides remain prohibited under the 2026 List.

4.3 Last regulatory review

Last regulatory review: 2026-05-14

5. Formulations and Routes

All formulations are investigational. No FDA-, EMA-, MHRA-, TGA-, Health Canada-, PMDA-, NMPA-, or MFDS-approved finished product exists.

RouteStatusNotes
Subcutaneous injectionInvestigational; dominant grey-market routeNo approved finished product. Community doses (200–500 µg/day) are not endorsed by any pharmacopoeia.
Intramuscular injectionInvestigationalCommunity route; no clinical-grade product.
Intra-articular injectionInvestigationalLee & Padgett 2021 retrospective case series (knee, n=16). [Peer-reviewed human study — low quality]
Oral tablet (PCO-02 / Bepecin)Investigational; Phase 1 onlyDiagen-developed for systemic delivery; NCT02637284 results withheld. Oral bioavailability of a 15-residue peptide expected to be low; not characterised in indexed publication.
Rectal enema (PL 14736)Investigational; Phase 2 onlyPL 14736 ulcerative-colitis program. Phase 2 published only as abstract (Gastroenterology 2005;128:A584). ⚠️
Topical / dermalInvestigationalPreclinical wound-healing models only; no human topical formulation in indexed registration.
IntranasalVendor-claimed onlyNo peer-reviewed human study; community route.
IntravenousInvestigationalLee & Burgess 2025 IV pilot, Altern Ther Health Med PMID 40131143. Small, low-tier journal.

Vendor-supplied “research peptide” lyophilised vials show variable QC; independent third-party testing of online lots has historically shown identity and purity failures.

6. Preclinical Evidence

Large in volume and narrow in source.

  • Tendon and ligament repair (rat). Transected Achilles, transected quadriceps, MCL transection: BPC-157 (typically 10 µg/kg IP or 10 ng/kg) reported to accelerate functional and biomechanical recovery. [Peer-reviewed preclinical — Staresinic 2003 J Orthop Res; Krivic 2008; Mikus 2001] 🔴
  • Gastric ulcer protection (rat, mouse). Ethanol, stress, NSAID (indomethacin, diclofenac, ibuprofen, aspirin), cysteamine models. [Peer-reviewed preclinical — Sikiric group, 1990s–2024] 🔴
  • NSAID injury reversal across organs (gut, liver, brain) at doses 10 µg/kg–10 ng/kg, rat. [Peer-reviewed preclinical — Sikiric group] 🔴
  • Spinal cord injury, traumatic brain injury, stroke (rat). Functional recovery, lesion size reduction. [Peer-reviewed preclinical — Sikiric group] 🔴
  • Angiogenesis — partially independent. Hsieh et al. 2017 (Chang Gung, Taiwan) demonstrated VEGFR2-dependent angiogenesis in CAM and rat hindlimb ischaemia. [Peer-reviewed preclinical — Hsieh 2017 PMID 27847966] — partial 🔴 mitigation.
  • Dopaminergic protection (MPTP, haloperidol catalepsy). [Peer-reviewed preclinical — Sikiric group] 🔴
  • Ischaemia–reperfusion remote-organ protection. Independent work from Gazi University (Ankara) in rats; lower-extremity I/R model, distant lung/kidney/liver protection. [Peer-reviewed preclinical — Gazi group 2025, PMC11857380] — partial 🔴 mitigation.
  • Toxicology. LD₁ “not achievable” in rat acute toxicity per Sikiric group; a more conventional GLP-style preclinical safety package reported (without full primary-data publication) by He et al. 2022. ⚠️🔴

The Vasireddi 2025 systematic review (HSS J, PMID 40756949) summarised 35 preclinical studies and one small human retrospective case series and concluded that, despite mechanistic plausibility, no preclinical study had been independently replicated outside of the originating laboratories with rigorous blinded, multi-centre methodology.

7. Clinical Evidence

Cochrane systematic reviews

None identified specific to BPC-157 / PL 14736 as of May 2026.

Pivotal RCTs

None. No completed Phase 3 trial exists for any indication in any jurisdiction.

PL 14736 IBD program (the only structured human dataset)

  • Phase 1 — Veljaca et al. 2003. Healthy male volunteers, rectal PL 14736 enema, single- and multiple-ascending-dose tolerability + limited PK. Published only as abstract in Gut 2003;51(Suppl III):A309. Reported safe and well-tolerated. ⚠️
  • Phase 2 — Ruenzi et al. 2005. Multicentre, randomised, double-blind, placebo-controlled trial of PL 14736 enema in mild-to-moderate ulcerative colitis. Presented at DDW 2005 and published as Gastroenterology 2005;128:A584 (abstract only). A full peer-reviewed manuscript with primary endpoint data was never published. The reason for non-publication is not in the public record. ⚠️
  • PCO-02 oral tablet — NCT02637284 (2015). Diagen-sponsored Phase 1a/1b in healthy volunteers, single- and multiple-dose oral PCO-02 (Bepecin 1 mg/tablet). Listed as “Unknown” / cancelled-results; no published full results. ⚠️

Other human reports

  • Lee & Padgett 2021. Retrospective uncontrolled case series, 16 patients, intra-articular BPC-157 ± TB-4 for knee pain. Subjective recall. Altern Ther Health Med 27(4):8–13. PMID 34324435. Low evidence tier.
  • Lee, Walker & Ayadi 2024. Pilot, interstitial cystitis symptom assessment. Altern Ther Health Med 30(10):12–17. Low evidence tier.
  • Lee & Burgess 2025. IV BPC-157 safety pilot. Altern Ther Health Med 31(5):20–24. PMID 40131143. Pilot tolerability only.
  • NCT07436547 (recruiting, 2025–2026). Hamstring-injury trial; recruiting per ClinicalTrials.gov.

There is no adequately powered, blinded, randomised controlled trial of BPC-157 for tendon, ligament, muscle, bone, joint, gut, or neurological indications published in an indexed peer-reviewed journal as of 14 May 2026.

7.5 Disputed Claims — Canonical Case

This section presents the central methodological dispute around BPC-157 without resolution. Both positions are supported by peer-reviewed publications currently coexisting in the literature; neither side has produced pre-publication independent replication of the other’s central claims.

Position A — The Sikiric / Seiwerth body of work. Predrag Sikiric, Sven Seiwerth and a long-standing collaborator group at the University of Zagreb School of Medicine have published, over approximately three decades, several hundred peer-reviewed preclinical papers asserting that BPC-157 produces wound healing, tendon and ligament repair, gastrointestinal mucosal protection, angiogenic effects via NO/VEGFR2 modulation, dopaminergic protection, multi-organ “cytoprotection→organoprotection,” and a safety profile in which LD₁ was not achievable in rodent dosing studies. Mechanistically the position is that BPC-157 modulates rather than over-drives angiogenesis and NO signalling, and therefore does not carry the theoretical tumorigenic or neurodegenerative liabilities that broad VEGFR2/eNOS agonism would predict. Funding is largely University of Zagreb / Croatian science programs, with an industry connection through the Pliva / Diagen PL 14736 era. ⚠️🔴 Representative citations:

  • Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des 2014;20(7):1126–1135. 🔴
  • Seiwerth S, Rucman R, Turkovic B, et al. Curr Pharm Des 2018;24:1972–1989. 🔴
  • Sikiric P, Sever M, Krezic I, et al. Pharmaceuticals 2023;16(7):1080. 🔴
  • Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals 2025;18(10):1450 (comment on Józwiak, PMID 41155565). 🔴

Position B — The Józwiak et al. critical analysis. Michalina Józwiak, Marta Bauer, Wojciech Kamysz and Patrycja Kleczkowska (Maria Skłodowska-Curie Medical Academy, Warsaw; Medical University of Gdańsk; National Medicines Institute, Warsaw) published a structured literature-and-patent review in Pharmaceuticals in January 2025:

  • Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals 2025;18(2):185. DOI 10.3390/ph18020185. PMID 40005999.

The authors argued:

  • The corpus is dominated by a single research group — by their tally over 80% of records returned for “BPC 157” in PubMed / Google Scholar trace to Sikiric and collaborators.
  • Studies routinely use a narrow dose range (10 µg/kg, 10 ng/kg) with limited dose–response characterisation.
  • No information on higher, repeated, or long-term human exposures; no formal carcinogenicity, reproductive-toxicity, or chronic-tox package.
  • The pro-angiogenic and NO-stimulating signal, if reproduced in long-term human use, raises theoretical concerns about tumorigenesis, free-radical injury, and contributions to neurodegenerative processes (Parkinson’s, Alzheimer’s) that the existing data do not resolve.
  • The therapeutic claims circulating in the optimization community substantially exceed what the published evidence supports.

The exchange that followed:

  • Sikiric et al. published a formal “Comment on Józwiak et al.”: Pharmaceuticals 2025;18(10):1450 (PMID 41155565), rebutting each of Józwiak’s risk claims and asserting that BPC-157 “controls” angiogenesis and NO functions rather than driving them. 🔴
  • Józwiak et al. issued a “Reply to Sikiric et al.”: Pharmaceuticals 2025;18(10):1451. In the reply they noted that the Sikiric group’s response did not address the single-group dependency, the narrow-dose-range issue, or the absence of long-term human data.

The disagreement is unresolved in the peer-reviewed literature as of 14 May 2026. Both positions remain on the public record; neither side has produced pre-publication independent replication of the other’s central claims.

Other disputes worth noting:

  • The 62-residue “body protection compound” parent protein from which BPC-157 is described as a partial sequence has not been independently confirmed as an annotated entry in UniProt or as a discrete, isolated, characterised protein outside the originating laboratory’s reports.
  • No formal retractions of BPC-157 primary studies were identified in a Retraction Watch / PubMed retraction search as of May 2026.

7B. Community Evidence Layer

Awareness arc. BPC-157 has one of the longest community footprints of any peptide currently in circulation — early bodybuilding boards (MESO-Rx, EliteFitness, Anabolic Minds) from the early 2010s, then r/Peptides from its 2014 founding (BPC-157 is the sub’s single most-discussed compound), then the Huberman / Rogan / Derek MPMD cluster of 2021–2024 that drove mass adoption. Joe Rogan Experience #1580 with Andrew Schulz (June 2022) — Rogan describing his elbow tendinitis “gone in two weeks” — is the most-cited inflection point. NBC News (2025) reported r/Peptides at ~100,000 subscribers and BPC-157 as “the peptide orthopedic surgeons receive the most patient questions about.”

Dominant protocol (community-canonical). ~250 µg/day or 250 µg BID (= 500 µg/day) SQ, 4–8 weeks on / 2–4 weeks off, abdomen-fat-pad standard for SQ or IM near injury for muscle-belly issues; reconstitution math anchored to the “5 mg vial + 2 mL bacteriostatic water = 2,500 µg/mL; draw 10 units on a U-100” template. Ben Greenfield’s “BPC 157: How To Use It To Heal Your Body Like Wolverine” (bengreenfieldlife.com, 2019–2024) is the most-cited single source; Huberman’s April 2024 episode anchored 300–500 µg “a few times per week, cycled”; Dr. Craig Koniver on Huberman Lab 2025 introduced “Pentadeca Arginate” as the post-FDA substitute, dosed ~500 µg in a bedtime stack with ipamorelin and tesamorelin.

Top claimed effects (frequency rank). Tendon/ligament healing (widespread — Rogan #1580/#1683, Greenfield, Derek MPMD on Attia #274, dozens of r/Peptides threads); joint pain reduction including the cancelled-knee-replacement Greenfield comment-thread anecdote (widespread); gut healing for IBS/IBD/leaky gut (common — primary rationale for oral arginate; Huberman noted it for “irritable bowel syndrome and colitis”); AAS-cycle / post-cycle tendon support (common — the original bodybuilder use case per Derek MPMD on Attia #274); wound/surgical recovery (common); GLP-1 GI side-effect mitigation (common, 2024–2026 wave). Occasional: sleep/mood (Koniver); hair regrowth (TikTok-era); cognitive/focus.

Top reported side effects. Injection-site reactions (common); “BPC palps” — heart palpitations (recurring forum tradition; vendors like Synthagen Labs publish cardio-defending blog posts framing it as “vasodilation, not arrhythmia”; community split between “lower the dose” and “you’re imagining it”); mild anxiety/irritability at high dose (Greenfield’s 2,500-µg overdose anecdote is the canonical example); stomach upset from oral (common); “stopped working after ~6 weeks” (recurring pattern catalogued by clinical blogs); cancer/angiogenesis fear at community level (widespread discussion, not personal report — Huberman cautioned against use with existing tumors, Derek MPMD: “the main discussion on BPC though is not whether it causes cancer, but whether it accelerates the growth of preexisting tumors”). No reports of acute serious toxicity surfaced in named community sources.

Dissent. Sikiric-dependency skepticism has bled into community discourse via Derek MPMD, the Orthoandwellness blog, and cross-posted Józwiak commentary on r/Peptides and r/Biohackers. “Doesn’t work for me” countercurrent threaded throughout r/Peptides (“I ran a full 5 mg vial on my elbow and felt nothing”). The arginate-is-superior vs arginate-is-rebrand split is unresolved: vendors who sell arginate (Peptide Sciences, Wise Choice, TheaWell, InfiniWell) cite patent-derived “93% stable at pH 3” data; skeptics treat the arginate wave as a vendor response to the FDA Category 2 designation. Near-the-injury vs systemic split persists (Greenfield = systemic; DosageTools / RealPeptides / Dr. Paulvin = local-to-injury). SQ has won as default over IM. Oral works-vs-scam is the most heated split.

Stack patterns. BPC-157 + TB-500 (“Wolverine Stack” / “the BPC-TB stack”) is the canonical pairing — coined by Greenfield, endorsed by Rogan, sold pre-blended (Celia Health “Snapback Stack”; Peptide Sciences “Repair and Recovery” capsules combining BPC-157 arginate with TB-4 fragment). Also: BPC + ipamorelin/CJC-1295 (Greenfield comment-thread; Koniver bedtime stack); BPC + GHK-Cu (skin/connective tissue, longevity-Twitter); BPC + tirzepatide/retatrutide/semaglutide (GLP-1 GI mitigation, 2024–2026 wave); BPC + KPV (gut micro-stack — both placed in FDA Category 2 in 2023); BPC during AAS post-cycle (legacy bodybuilding).

Vendor channel and 2023–2026 supply migration. Pre-2023: compounding pharmacies (Tailor Made Compounding the dominant player, until the October 2020 DOJ guilty plea against Tailor Made Compounding LLC and owner Jeremy Delk, sentenced February 2021 with $1,788,906.82 forfeiture, BPC-157 named in the plea agreement — the channel’s foundational regulatory shockwave but did not slow demand). September/October 2023 FDA Category 2 designation forced migration into three post-2023 channels: (1) “research-chemical” grey-market injectable vendors (Peptide Sciences, Limitless Life, Amino Asylum, Pure Peptides, BioLongevity Labs, Modern Aminos, Core Peptides — COA practices vary; Peptide Sciences and Limitless Life publish Janoshik third-party COAs per batch, smaller vendors per-brand only); (2) the arginate-salt rebranding wave (2024–2026) marketing “BPC-157 arginate” / “Pentadeca Arginate” / “Penta Deca Peptide Arginate” as separate compounds, framed as a regulatory workaround (Peptide Sciences, ProHealth Longevity, Wise Choice, TheaWell, InfiniWell, Annular, Real Peptides, SeekPeptides — many with direct affiliate relationships to biohacker outlets); (3) telehealth-supervised channels selling “Pentadeca Arginate” under claimed physician oversight (Celia Health, The Piazza Center, Liquid Mobile IV). Price range observed 2025–2026: injectable 5 mg vials commonly $25–$60 from research-chem vendors; arginate capsule bottles (60–90 ct) commonly $90–$180 from telehealth/wellness vendors.

February 27, 2026 reclassification announcement (RFK Jr. on JRE #2461): HHS signaled approximately 14 peptides including BPC-157 would be moved back to Category 1, with formal FDA action expected mid-2026. Community read this as validating both the grey-market patience strategy and the arginate-rebrand strategy.

Community Score: 85 / 100 (Usage 25/25; Codification 21/25; Effect consistency 14/25; Time-in-circulation 25/25). This is among the highest community scores in the catalog — points lost only on effect-consistency (the “stopped working” countercurrent + cancer overhang) and modest codification splits (SQ-vs-IM-vs-oral, acetate-vs-arginate).

8. Safety Profile

Preclinical safety (rodent). Reported as exceptionally favourable: LD₁ not achievable across acute and sub-chronic dosing per the originating laboratory’s published toxicology. 🔴 Independent GLP-style PK/safety package: He et al. 2022 (Chinese group), reporting plasma t½ of minutes, hepatic metabolism, renal clearance, no overt toxicity at studied doses.

Human safety from PL 14736 Phase 1/2. Veljaca 2003 (Phase 1) reported the rectal enema was safe and well tolerated in healthy male volunteers; specific AE table is not in the indexed abstract. Ruenzi 2005 (Phase 2 abstract) reported acceptable tolerability; the absence of full publication means the AE table cannot be independently verified. ⚠️

Human safety from pilot reports. Lee & Padgett 2021 (n=16, intra-articular knee) and Lee & Burgess 2025 (IV pilot) reported no serious adverse events; sample sizes are inadequate for safety inference.

FAERS / CAERS signals. Secondary commercial commentary refers to a small number of adverse-event reports in FAERS (2021, 2023) and a life-threatening event in CAERS associated with products containing BPC-157, but the FDA databases do not adjudicate causality and the reports may reflect adulterated grey-market product rather than the active substance. ⚠️

Theoretical concerns.

  • Oncological risk via VEGFR2 upregulation and pro-angiogenic signalling — central to the Józwiak critique. Unresolved.
  • Cardiovascular effects via Akt-eNOS / NO modulation — theoretical interaction with vasoactive drugs; community “BPC palps” reports may sit in this space.
  • Immunogenicity of a non-self synthetic peptide on repeated subcutaneous dosing — uncharacterised.
  • Vendor / product quality. Grey-market sourcing produces real-world identity, purity, and endotoxin risks that are functionally a safety issue distinct from intrinsic pharmacology. [Regulatory document — Health Canada / TGA seizure advisories]

Trial exclusions. PL 14736 excluded pregnant / nursing patients, severe-extent UC, recent biologic therapy; full exclusion criteria not in the indexed abstract.

Special populations. No data — pregnancy, lactation, paediatrics, hepatic/renal impairment.

Long-term safety. Unknown. The longest documented human exposure in registered trials was the PL 14736 Phase 2 dosing window (weeks). Community use extends to months or years with no systematic surveillance.

Retraction status. No retractions of primary BPC-157 studies identified as of May 2026.

Community-reported AEs requiring science-layer attention.

  1. Heart palpitations (“BPC palps”) — widespread community report, no clinical characterisation; mechanistically plausible via NO-pathway modulation.
  2. “Stopped working after ~6 weeks” — recurring community pattern catalogued by clinical blogs (Revolution Health); not characterised in either pharmacology (tachyphylaxis? receptor desensitisation?) or clinical literature.
  3. Mild anxiety / irritability at high dose — single high-credibility anecdote (Greenfield 2,500 µg); not characterised.

9. Drug Interactions

No formal human drug-interaction studies exist. Theoretical interactions reasoned from mechanism:

  • Anticoagulants / antiplatelets — additive bleeding-time effects plausible via NO-pathway modulation. [Theoretical] 🔴
  • VEGFR-pathway oncology drugs (bevacizumab, sunitinib, sorafenib, axitinib, ramucirumab) — theoretical antagonism given proposed VEGFR2 upregulation. [Theoretical]
  • Nitric oxide donors (nitrates), PDE5 inhibitors — theoretical hemodynamic potentiation. [Theoretical]
  • NSAIDs — preclinical data describe BPC-157 as protective against NSAID GI injury; whether this translates to humans is unknown. [Theoretical] 🔴
  • Corticosteroids and immunosuppressants — no characterised interaction.
  • GLP-1RAs (semaglutide, tirzepatide, retatrutide) — no interaction data despite widespread community co-administration for GI side-effect mitigation.
  • Endogenous AAS/exogenous testosterone — no interaction data despite widespread legacy bodybuilding co-administration.

State of evidence: no formal human interaction studies. All interactions above are mechanism-derived speculation.

10. Research Gaps

  1. Adequately powered Phase 2/3 musculoskeletal RCTs. None completed; one hamstring-injury study (NCT07436547) recruiting.
  2. Independent replication of Sikiric-group preclinical efficacy in blinded multi-centre rodent studies outside Zagreb. 🔴
  3. Long-term human safety at any dose, any route.
  4. Oncological risk characterisation. Carcinogenicity bioassay; tumour-bearing model behaviour.
  5. Formal human PK studies for SC, IM, and oral routes, with validated bioanalytical methods.
  6. Pediatric and elderly data. Absent.
  7. Drug interaction studies. Absent.
  8. Immunogenicity / anti-drug-antibody characterisation under chronic dosing.
  9. Standardised analytical reference method for anti-doping; WADA has not published a BPC-157-specific Technical Document.
  10. Independent confirmation of the 62-residue parent protein in human gastric juice via modern proteomic methods.
  11. Full publication of PL 14736 Phase 2 primary data — the central human dataset remains an abstract.
  12. Reproducibility audit of the highest-citation Sikiric-group efficacy studies.
  13. Mechanistic explanation for the “BPC palps” community signal if real.
  14. Mechanistic explanation for the “stops working at ~6 weeks” community pattern if real.
  15. Independent characterisation of arginate vs acetate salt in vivo — currently a vendor-driven claim resting largely on patent stability data from the originating commercial chain.

11. Bottom-Line Encyclopedia Note (≤150 words)

BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) with a 30-year preclinical record concentrated almost entirely in a single Zagreb research group, partially mitigated by a small number of independent replications of the VEGFR2/angiogenesis signal. The only structured human dataset is the Pliva/Diagen PL 14736 ulcerative-colitis program (Phase 1 and Phase 2), and that Phase 2 has never appeared as a full peer-reviewed publication. No regulator has approved BPC-157 for any indication. The FDA placed it in 503A Category 2 in 2023; the nominations were subsequently withdrawn and a PCAC consultation is scheduled for 23 July 2026. Australia has imposed Schedule 4 plus Appendix D (possession illegal without authority) since 1 June 2024. WADA has prohibited it under S0 since January 2022; CCES/USADA sanctions are accumulating. Community use is widespread and substantially ahead of formal evidence. Oncological and long-term safety questions remain open.

11B. Gap Analysis — Where Science and Community Diverge

BPC-157 sits in the High community + Low science cell of the gap matrix, subclassified “untested” for the primary musculoskeletal indication (no completed RCT) and “tested-mixed but never fully published” for the IBD indication (PL 14736 Phase 2 abstract only). The science/community delta (D7 vs C85, Δ = 78 points) is the largest in the encyclopedia currently — larger than retatrutide (Δ = 8), tirzepatide (Δ = 14), or MOTS-c (Δ = 27 with the opposite sign).

TopicScience LayerCommunity LayerGap
Tendon/ligament efficacy (the central community claim)Zero completed RCTs in humans. All human “evidence” is uncontrolled case series (Lee & Padgett 2021, n=16) or anecdote. Vasireddi 2025 systematic review: no preclinical study independently replicated outside originating labs with rigorous methodology.”Cured my elbow in two weeks” — Rogan #1580. Widespread consistent claim across Greenfield, Huberman, Derek MPMD, dozens of r/Peptides threads.🔴 MAJOR GAP — untested. Community is reporting a clinical effect that has never been tested under controlled conditions in humans. Not tested-negative, not tested-mixed. Untested.
Gut/IBD efficacyPL 14736 Phase 2 enema (Ruenzi 2005) reported acceptable tolerability in mild-moderate UC; primary endpoint data never published. ⚠️ No follow-up Phase 3.Oral arginate marketed for IBS/IBD/leaky gut/ulcers (Huberman April 2024 referenced “irritable bowel syndrome and colitis”). Heavy vendor presence.Community ahead of an abandoned program. The compound’s strongest historical clinical signal (rectal PL 14736 for UC) is being repurposed by community into oral arginate capsules for “leaky gut” — a route, formulation, and indication for which no human evidence exists.
VEGFR2/angiogenesis mechanismHsieh 2017 (Chang Gung) independently replicated; multiple Sikiric-group papers describe it as central. Józwiak 2025 raises this exact mechanism as the theoretical oncology risk.Huberman explicitly cautioned against use with existing/concerning tumors (April 2024). Derek MPMD framed cancer concern as “not whether it causes cancer, but whether it accelerates preexisting tumors.” Orthoandwellness blog widely cross-posted on r/Peptides.Aligned. This is the one place where science and community have converged on the risk — community has absorbed the Józwiak concern faster than it usually absorbs critical literature.
”BPC palps” (community report)Not characterised in any clinical literature. Mechanistically plausible via NO-pathway modulation.Recurring forum tradition; Synthagen Labs vendor blog responds with “vasodilation, not arrhythmia” framing. Community split between “lower dose” and “you’re imagining it.”Community-only signal that science has not addressed. Real-world AE pattern unevaluable in either direction.
”Stops working after ~6 weeks”Not characterised. No tachyphylaxis or receptor-desensitisation data.Recurring pattern catalogued by Revolution Health & Wellness clinical blog and threaded across r/Peptides.Community-only signal that science has not addressed. The community has surfaced a pharmacodynamic pattern that the published literature is silent on.
Dose responseSikiric corpus uses narrow 10 µg/kg or 10 ng/kg range; Józwiak flags this as a methodological hole. No human dose-finding study exists.Community converges on ~250–500 µg/day SQ for adults — a dose extrapolated from rat µg/kg with no human bridging.Both layers underspecified. The community-canonical dose is not anchored in any human PK or PD study.
Single-group dependencyFlagged 🔴 by Józwiak 2025 and by the Vasireddi 2025 systematic review.Has bled into community discourse (Derek MPMD; Orthoandwellness; cross-posted Józwiak commentary). Defenders counter “30-year head start.”Aligned in awareness, split in interpretation. Community knows about the dependency; the community is divided on whether it disqualifies the corpus.
PL 14736 Phase 2 never publishedDocumented and flagged. Reason for non-publication not in public record.Largely unaware. Community speaks of “BPC has Phase 2 data for IBD” without registering that the data are abstract-only.🔴 Community misreads the abstract as a published trial. The single most-cited human data point for BPC-157 is in fact a conference abstract whose primary endpoint data have never been peer-reviewed.
Arginate vs acetatePatent-stability data exist for the arginate salt at pH 3; no independent in vivo head-to-head.Active vendor wave (Peptide Sciences, Wise Choice, TheaWell, InfiniWell). Community split between “arginate is a real upgrade” and “arginate is a regulatory-workaround rebrand.”Vendor-driven, not science-driven. The salt distinction is real chemistry but the clinical superiority claim rests on commercial sources, not independent comparison.
WADA S0 prohibitionExplicit; sanctions accumulating (Brooks 4-yr, Thrones 5-yr, Lute 1-yr).Aware. Community treats this as orthogonal to non-athlete use.Aligned absence rather than gap — community knows but doesn’t care. Users in WADA-tested sport contexts face strict-liability exposure independent of efficacy questions.
TGA Schedule 4 + Appendix DExplicit (effective 1 June 2024).Aware via legal-status pages (RethinkPeptides; Holt Law). Australian users face possession risk.Aligned in awareness.
Vendor identity / qualityFlagged via Health Canada, TGA seizure advisories.Active community concern (Janoshik retesting culture, COA per-batch vs per-brand split).Aligned in awareness — and community has built mitigation infrastructure (third-party COA culture) that science alone has not.

Net characterisation. BPC-157 is the canonical “community ahead of science” case in the encyclopedia. Not because the community is hyping a fully tested-negative compound (it isn’t tested-negative — it’s untested), and not because community claims are wholly delusional (the VEGFR2 mechanism is real preclinically, partially independently replicated, and the “tendon healing” claim has some preclinical anchor). Rather, because a fifteen-year community protocol literature, a vendor ecosystem in the tens of millions of dollars, and an evidence base of zero completed Phase 2/3 RCTs coexist around the same molecule. The three highest-consequence gaps:

  1. The central community claim — “BPC heals tendons in two weeks” — has never been tested under controlled conditions in humans. Not at the community-canonical 250 µg/day, not at any dose, not by any route. The recruiting hamstring trial (NCT07436547) is the first attempt.
  2. The single most-cited human data point for BPC-157 (PL 14736 Phase 2 UC) is a conference abstract whose primary endpoint data have never been peer-reviewed. Twenty-one years on.
  3. The oncology theoretical concern (Józwiak 2025) targets the exact mechanism (VEGFR2 upregulation, NO modulation) that the Sikiric group cites as the positive feature of the molecule. The Sikiric reply frames this as “modulation, not over-drive”; the unresolved Józwiak counter-reply notes that “modulation” is asserted, not demonstrated, in long-term human exposure data — because no such data exist.

The community has been right about one thing the science is too slow on: vendor identity and product quality have become a real-world safety issue independent of intrinsic pharmacology, and the community’s Janoshik-retesting culture has become a functioning, if informal, post-market surveillance system that no regulator has yet matched.

12. Three Paths

You choose your risk tolerance. This monograph provides the data, not the recommendation.

Conservative path — wait. Defined as: not engaging until at least one of (a) full peer-reviewed publication of the PL 14736 Phase 2 primary endpoint data (twenty-one years pending), (b) publication of NCT07436547 (hamstring injury, recruiting), (c) regulatory approval in at least one major jurisdiction, (d) independent multi-centre replication of any Sikiric-group efficacy study with blinded methodology, or (e) the 23 July 2026 PCAC outcome producing a clear 503A pathway. All five gates are pending as of 14 May 2026. BPC-157 does not meet the conservative bar — at all. Conservative-path users wait.

Moderate path — Tier D with supervision. Defined as: treating BPC-157 as a Tier-D compound with preclinical mechanistic plausibility, no human RCT evidence, an unresolved oncology concern, and a real anti-doping exposure for any tested-sport athlete. This path means: pre-cycle baseline including complete blood count, comprehensive metabolic panel, lipid panel, hs-CRP, and either tumor-history exclusion or oncology consultation if any concerning family history; on-cycle monitoring at 6–8 weeks for the “BPC palps” pattern (resting HR, BP, ECG if symptomatic); supply via a compounding pharmacy operating under physician oversight rather than research-chem grey market; explicit avoidance during any active malignancy or known precancerous lesion; explicit avoidance for any WADA-tested athlete or DoD service member; awareness of the Australian Schedule 4 + Appendix D possession risk; absolute avoidance during pregnancy/lactation (no data). The moderate path treats Tier D as “preclinical plausibility, monitor the safety signals the community has surfaced because formal pharmacovigilance does not exist.”

High-tolerance path — grey-market with mitigation. Defined as acknowledging that none of the five conservative gates are met, that all efficacy claims rest on a single research group + community anecdote, that the 12-month-plus community-canonical cycle pattern has no published safety analog, and that grey-market product identity is not guaranteed. The community mitigation stack as it is actually practiced: third-party COA verification (Janoshik Analytical or MZ Biolabs) of the specific vial — the community has built this infrastructure because regulators have not; preference for vendors that publish per-batch (not per-brand) COAs with mass-spec identity confirmation; titration starting at 250 µg/day rather than the 500 µg/day BID community-canonical; cap at the lower end of the community range; structured bloodwork on the optimization-community schedule; oncology screening proportionate to age and family history; explicit refusal to layer with any vasoactive medication without physician dialogue; awareness that the “Pentadeca Arginate” rebrand is a regulatory-workaround commercial position with no independent in vivo head-to-head data against the acetate salt; if used during a GLP-1RA cycle, explicit understanding that the GI-mitigation framing has no clinical evidence base.

13. Key References

Scientific

Regulatory documents:

  • FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. Current version, retrieved May 2026.
  • FDA. Pharmacy Compounding Advisory Committee Meeting Notice, 23–24 July 2026.
  • TGA. Notice of Final Decision to Amend the Poisons Standard — ACMS-43 / ACCS-37 / Joint ACMS-ACCS-35, March 2024.
  • OPSS / DoD. BPC-157: A prohibited peptide and an unapproved drug. Operation Supplement Safety.

Anti-doping documents:

  • WADA. 2026 Prohibited List, effective 1 January 2026. BPC-157 under S0.
  • USADA. BPC-157 substance profile.
  • Sport Integrity Canada (CCES) press releases: Emma Brooks (7 April 2025); Mikal Thrones (24 February 2025); 2026 non-approved peptide reminder (27 April 2026).
  • Global DRO cross-check, 14 May 2026.

Peer-reviewed human studies (all low evidence tier):

  • Veljaca M et al. Gut 2003;51(Suppl III):A309. Abstract. ⚠️
  • Ruenzi M et al. Gastroenterology 2005;128:A584. Abstract. ⚠️
  • Lee E, Padgett B. Altern Ther Health Med 2021;27(4):8–13. PMID 34324435.
  • Lee E, Walker C, Ayadi B. Altern Ther Health Med 2024;30(10):12–17.
  • Lee E, Burgess K. Altern Ther Health Med 2025;31(5):20–24. PMID 40131143.

Clinical trial registrations:

  • NCT02637284 — PCO-02 (Bepecin), Diagen, 2015.
  • NCT07436547 — BPC-157 hamstring injury, recruiting 2025–2026.

Systematic review:

  • Vasireddi N et al. HSS J 2025. DOI 10.1177/15563316251355551. PMID 40756949.

Critical review and exchange (Section 7.5):

  • Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals 2025;18(2):185. PMID 40005999.
  • Sikiric P et al. Pharmaceuticals 2025;18(10):1450. PMID 41155565. 🔴
  • Józwiak M et al. Pharmaceuticals 2025;18(10):1451.

Selected preclinical (illustrative — full corpus much larger):

  • Hsieh MJ et al. J Mol Med 2017;95:323–333. PMID 27847966. [Independent of Zagreb]
  • Chang CH et al. J Appl Physiol 2011;110:774–780. [Chang Gung, independent]
  • Chang CH et al. Molecules 2014;19(11):19066–19077. PMID 25415479. [Independent]
  • Seiwerth S et al. Curr Pharm Des 2018;24:1972–1989. 🔴
  • Sikiric P et al. (multiple Pharmaceuticals 2023–2025 reviews). 🔴
  • He L et al. PK/distribution/metabolism. 2022. [Independent]
  • Gazi University group. PMC11857380 (2025). [Independent]

Analytical / anti-doping:

  • Cox HD, Miller GD, Eichner D. Drug Test Anal 2017;9:1490–1498. PMID 28371416.

Community

  • Huberman Lab podcast, “Benefits & Risks of Peptide Therapeutics,” April 1, 2024 — BPC-157 segments 14:48, 21:50, 27:53.
  • Huberman Lab w/ Dr. Craig Koniver, 2025 — “Pentadeca Arginate” introduction; bedtime BPC + ipamorelin + tesamorelin stack.
  • Andrew Huberman, X/Twitter, Mar 29, 2024 — tumor-risk caution.
  • Joe Rogan Experience #1580 with Andrew Schulz, June 2022 — “elbow tendinitis gone in two weeks.”
  • JRE #1683 with Andrew Huberman — Wolverine Stack discussion.
  • JRE #2440 with Matt Damon & Ben Affleck, January 2026 — “heal like you’re a six-year-old.”
  • JRE #2461 with RFK Jr., 27 Feb 2026 — Category 1 reclassification announcement.
  • JRE #2469 with Brigham Buhler, 18 March 2026.
  • Ben Greenfield, “BPC 157: How To Use It To Heal Your Body Like Wolverine” — bengreenfieldlife.com.
  • Peter Attia, The Drive #274 — Derek (More Plates More Dates), August 2023 — BPC segment at 3:12:00.
  • Derek (More Plates More Dates) TikTok cuts — cancer-risk framing.
  • DosageTools — “BPC-157 Dosing Protocol.”
  • RealPeptides.co — “BPC-157 Dosage Protocol Guide” and “BPC 157 Arginate Salt.”
  • Wise Choice Supplements; TheaWell; SeekPeptides; PeptideDeck; Peptide Sciences “Repair and Recovery”; InfiniWell; ProHealth Longevity; Annular; Real Peptides — vendor pages, commercial motive flagged.
  • The Piazza Center clinic blog; Brainflow.co; JoeRoganPeptides.com — clinic and biohacker-blog secondary sources, affiliate relationships flagged.
  • Revolution Health & Wellness — “Common Mistakes Using BPC-157 or TB-500 Alone.”
  • Orthoandwellness.com — “BPC-157: Miracle Healing Peptide or Hidden Danger?”
  • DOJ press release, 24 Feb 2021 — Tailor Made Compounding $1,788,906.82 forfeiture; BPC-157 named in plea.
  • Paulick Report; BloodHorse — Tailor Made coverage.
  • NBC News (2025) — Dr. Travis Dekker quote; r/Peptides ~100,000 subscribers.
  • RethinkPeptides; Holt Law; Safe Harbor Group; Armstrong & Bradylyons LLC — regulatory-status community-readable summaries.

14. Audit / Refresh Trail

  • Composed: 14 May 2026
  • Next refresh triggers:
    • FDA PCAC vote 23–24 July 2026 — outcome decides 503A compounding pathway for BPC-157 free base and acetate; this is the single largest pending regulatory event.
    • First peer-reviewed publication of NCT07436547 (hamstring injury) — would be the first BPC-157 RCT in the modern indexed literature.
    • Any full peer-reviewed publication of PL 14736 Phase 2 primary data — twenty-one years pending; would materially change the IBD evidence picture.
    • Any retraction of a primary Sikiric-group efficacy study — flagged for Retraction Watch monitoring.
    • Any independent multi-centre replication of a high-citation Sikiric study with blinded methodology.
    • Any new analytical Technical Document from WADA specifically for BPC-157.
    • TGA Schedule 4 + Appendix D revision or any other major-jurisdiction regulatory action.
    • Any vendor scandal or COA-fraud event affecting the BPC-157 supply chain at scale beyond the 2020 Tailor Made precedent.
    • Mainstream-podcast adoption shift — if Huberman, Attia, or Rogan publicly retract their previous favorable framing, that’s an inflection-point event for the community-layer score.
    • Direct r/Peptides / r/Biohackers thread retrieval to ground community-layer evidence in primary thread permalinks with vote counts (current corpus is named-source-heavy but Reddit-direct-thin).

15. Comparative-table note

New class identified: Tissue repair / wound peptides — BPC-157, TB-500/Tβ4, Pentadeca Arginate (PDA), GHK-Cu, AHK-Cu, Matrixyl, cibinetide/Ara-290.

Action: Create the comparative tissue-repair table once a second compound in this class is composed for the encyclopedia. The natural next compound is GHK-Cu — research material has been compiled and only the composition step remains before it is ready for cross-reference. TB-500/Tβ4 is the second-most-natural — the BPC + TB-500 “Wolverine Stack” is the canonical community pairing for BPC-157, making the comparative table immediately useful to community readers the moment TB-500 is composed.

Fields the new row will affect (when the table is built): WADA status (BPC-157 S0; GHK-Cu not currently prohibited; TB-500 S2.1), FDA 503A category (all three in flux post-2023 Category 2 nominations), TGA scheduling (BPC-157 Schedule 4 + Appendix D; GHK-Cu cosmetics-permitted; TB-500 unscheduled), evidence tier (BPC-157 D7 musculoskeletal; GHK-Cu likely B-tier; TB-500 likely D-tier), single-group dependency flag (BPC-157 🔴 Zagreb; GHK-Cu 🔴 Pickart; TB-500 🔴 Goldstein/Kleinman), community score (BPC-157 C85; GHK-Cu C76; TB-500 likely ≥C75).